

Accepted Manuscript

The 2017 Royal Society Of Medicine Cystic Fibrosis Symposium

CFTR modulator therapy in patients with cystic fibrosis and an organ transplant

Ruth M. Mitchell, Andrew M. Jones, Peter J. Barry

PII: S1526-0542(18)30057-5

DOI: <https://doi.org/10.1016/j.prrv.2018.04.003>

Reference: YPRRV 1255

To appear in: *Paediatric Respiratory Reviews*



Please cite this article as: R.M. Mitchell, A.M. Jones, P.J. Barry, CFTR modulator therapy in patients with cystic fibrosis and an organ transplant, *Paediatric Respiratory Reviews* (2018), doi: <https://doi.org/10.1016/j.prrv.2018.04.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CFTR modulator therapy in patients with cystic fibrosis and an organ transplant

Ruth M Mitchell¹, Andrew M Jones^{1,2}, Peter J Barry^{1,2}

1. Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Manchester, UK
2. University of Manchester, Manchester, UK

Corresponding author

Dr Peter Barry, Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Manchester, UK

peter.barry@mft.nhs.ukl

Conflicts of interest:

Dr. Barry has received speaker fees and participated in advisory boards for Vertex pharmaceuticals. He is an investigator on 4 clinical trials funded by Vertex pharmaceuticals and is the co-chair of an educational conference which received sponsorship from Vertex pharmaceuticals

Prof Jones is the co-chair of an educational conference which received sponsorship from Vertex pharmaceuticals

Keywords

Cystic fibrosis, organ transplantation, CFTR modulators, drug interactions

Abstract

CFTR modulators are a class of drugs which directly target the defective CFTR protein in cystic fibrosis (CF), improving its function with resultant clinical improvements. Currently these drugs are confined to people with a limited selection of genetic mutations. New

Download English Version:

<https://daneshyari.com/en/article/8952758>

Download Persian Version:

<https://daneshyari.com/article/8952758>

[Daneshyari.com](https://daneshyari.com)